Healthcare >> CEO Interviews >> October 17, 2003
DONALD D. TARTRE is Vice President and Chief Financial Officer of
Stressgen Biotechnologies Corporation. Mr. Tartre has extensive
financial experience with major pharmaceutical and biotechnology
companies. He joined Stressgen in March 2001 from Agouron
Pharmaceuticals, Inc., where he served as Vice President, Finance &
Planning and Corporate Controller. Prior to Mr. Tartre's four-year
tenure at Agouron, formerly a public biotechnology company engaged in
the discovery, development and marketing of pharmaceutical products that
became a subsidiary of Pfizer Inc. in 2000, he served seven years as
Controller of Gen-Probe Incorporated, a leading bioscience company in
the medical diagnostics industry. Before joining Agouron and Gen-Probe,
Mr. Tartre worked with Ernst & Young for seven years and Columbia/HCA
for one year. Mr. Tartre is a Certified Public Accountant and a
Certified Management Accountant, and received a BS in Business
Administration from the University of Southern California. Profile
the company today?
Mr. Tartre: First, I would like to repeat our usual warning that some of
the statements that I'm making
